• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen to attend AACR 2026 in San Diego, 17-22 April 2026

Apr 17, 2026 | Past Events

Dr. Matilde Bocci is presenting a poster entitled “FAP-targeting Small molecule-immunostimulator conjugate bearing a novel TLR7 agonist payload induces tumor eradication and long-lasting antitumor immunity in vivo”. Dr. Abdullah Elsayed is presenting a...

Philogen to attend EADO 2026, 23-25 April 2026

Apr 17, 2026 | 2026, Events, Past Events, Scientific

Prof. Thomas Eigentler will give a talk entitled “Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort”. Follow the link for more details.

Philogen is pleased to invite you to an upcoming webinar on March 30, 2026, at 15:00 GMT | 16:00 CET

Mar 30, 2026 | 2026, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.

Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.

Nov 20, 2025 | 2025, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link in the description or contact usat IR@philogen.com for further details.

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Oct 1, 2025 | 2025, Events, Past Events, Scientific

Dr. Emanuele Puca will give an oral presentation entitled: “Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results” Dr. Roberto de Luca will give an oral presentation entitled: “Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for...

Philogen is pleased to invite you to an upcoming webinar on September 26, 2025, at 14:00 GMT | 15:00 CET.

Sep 26, 2025 | 2025, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.
« Older Entries

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it